<DOC>
	<DOCNO>NCT00844142</DOCNO>
	<brief_summary>Efficacy - To assess efficacy etanercept versus sulfasalazine add NSAIDs patient moderate severe active early axial spondyloarthritis duration ongoing axial symptom le 5 year . Primary outcome change active inflammatory lesion sacroiliac joint spine detect MRI 12 month . Secondary outcome parameter clinical laboratory efficacy parameter MRI change 6 month 2 year . Comparisons make within two treatment arm compare baseline . At 1 year extension phase comparison also make year 1 year 2 . At end extend study pelvic x-ray plan .</brief_summary>
	<brief_title>Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis ( AS )</brief_title>
	<detailed_description>Randomized control study two treatment arm ( Phase II ) , 1 year open extension Efficacy - To assess efficacy etanercept vs. sulfasalazine add NSAIDs patient moderate severe active early axial spondyloarthritis duration ongoing axial symptom le 5 year . Primary outcome change active inflammatory lesion sacroiliac joint spine detect MRI 12 month . Secondary outcome parameter clinical laboratory efficacy parameter MRI change 6 month 2 year . Comparisons make within two treatment arm compare baseline . At 1 year extension phase comparison also make year 1 year 2 . At end extend study pelvic x-ray plan . For etanercept group : To assess whether etanercept show sustain long term response 1 year . To assess whether etanercept slow stop progression show MRI.For sulfasalazine group : ass whether etanercept show long term response 1 year . To assess whether etanercept slow stop progression show MRI . For patient remission duration remission assess maximum one year . In case flare disease patient ( re- ) treat etanercept efficacy assess . Safety - To study long-term safety etanercept patient moderate severe active early axial spondyloarthritis compare patient treated sulfasalazine period one year . Patients treat 1 year either etanercept 2x25mg per week subcutaneously sulfasalazine 2g/ day give orally . Following screen baseline evaluation , patient assess week 2 , 4 , 6 , 8 , 10 , 12 , 24 , 36 48 . Efficacy safety measurement record throughout entire study . The study follow 60 week follow-up phase week 48 ( end treatment phase ) . In case flare ( re- ) treat etanercept 60 week ( week 108 ) . All patient former etanercept group remission continue treat etanercept 60 week ( week 60 , 72 , 84 , 96 , 108 ) . All patient former sulfasalazine group remission switch etanercept 60 week ( week 50 , 54 , 60 , 72 , 84 , 96 , 108 ) . Treatment arm : Arm 1 : 40 patient receive etanercept 2x25 mg weekly subcutaneous injectionArm 2 : 40 patient receive sulfasalazine 2 g/day ( 3 g/ per day ) Duration study:12 month . For patient remission 12 month follow period enclose . Treatment continue patient case flare patient achieve remission 60 week . The study plan start September 2005 . Patients recruit 12 month period . Altogether duration study 51 month . All patient willing participate extension treat another 60 week . Patient Population : Only active axial SpA patient disease duration ( measured time ongoing spinal symptom ) less 5 year include . This imply patient radiological evidence sacroiliitis ( fulfil modify New York criterion AS ) without radiological evidence sacroiliitis ( see inclusion criterion ) include . Efficacy Variables : Primary endpoint : · Reduction active inflammatory lesion MRI 12 monthsSecondary endpoint : - ASAS 20 % , 40 % , 70 % response , ASAS criteria partial remission· BASDAI 20 % , 50 % , 70 % improvement · BASFI · Mobility examination : BASMI , Chest Wall Expansion· disease control antirheumatic therapy criterion ( DC-ART20 ) ( 5 6 ) *· CRP , ESR· Quality Life : SF-36· Numeric Rating Scale ( NRS ) - physician global , patient global , general pain , nocturnal pain · Enthesitis index ( Maastricht scale ) · swollen joint count· EQ-5D· Socio-economic questionnaire· Chronic change MRI 6 , 12 month 108 weeks· Reduction active inflammatory lesion MRI 6 month chronic lesion 6 12 month 108 week</detailed_description>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>Patients 18 50 year age moderate severe active axial spondyloarthritis . Diagnosis make : Chronic low back pain ( duration &gt; 3 month , onset &lt; 45 year age ) plus 3 6 follow criterion image positive 4 follow 6 criterion image negative · Inflammatory back pain : Good good response NSAIDs One follow extraspinal manifestation : uveitis , peripheral arthritis , enthesitis , HLAB27 positive Positive imaging : MRI show acute inflammatory lesion spine SIJ ( past ) bilateral sacroiliitis grade 24 unilateral sacroiliitis grade 34 xray old 12 month Positive family history SpA MRI screen show acute inflammatory lesion SIJ spine Active disease define : BASDAI score &gt; =4 back pain score ( BASDAI question 2 ) &gt; = 4 despite concurrent NSAID therapy , intolerance NSAIDs . Other inclusion criterion include , prednisone : &lt; 7.5 mg per day stable 4 week prior baseline Women child bear potential must negative pregnancy test study baseline use adequate , effective method contraception duration 6 month stop etanercept therapy . Sexual active men must use accepted method contraception duration 6 month stop etanercept therapy . Reading normal chest/lung xray perform within last 12 week inclusion Able selfadminister injectable drug supply caregiver . Able store injectable test article 2° 8° C. Disease duration longer 5 year History active tuberculosis ( TB ) , histoplasmosis listeriosis . History positive HIV status , know hepatitis B C History malignancy carcinoma situ cervix adequately treat nonmetastatic squamous basal cell skin carcinoma . Antibiotic treatment within 3 week prior screen . Previous treatment TNFalpha blocker Treatment sulasalazine last 6 month participation clinical trial severe internal medical disease severe cardiac , hepatic , gastrointestinal , neurological , psychiatric disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>ankylose spondylitis</keyword>
	<keyword>axial spondyloarthritis</keyword>
	<keyword>magnetic resonance imaging</keyword>
	<keyword>etanercept</keyword>
	<keyword>sulfasalazine</keyword>
</DOC>